Pittsburgh Review

Vascular surgeons at Allegheny General Hospital (AGH) in Pittsburgh are participating in a clinical trial that explores the use of artificial intelligence to detect deep vein thrombosis (DVT) in cardiac patients. AGH, part of the Allegheny Health Network (AHN), is the first institution in western Pennsylvania and the third nationwide to join this study.

The trial involves collaboration with ThinkSono, a UK-based AI company. Together with AHN’s Cardiovascular Institute, they aim to diagnose DVT using an AI-powered ultrasound technology. This approach allows clinicians to capture images using a handheld scanner and smartphone, moving DVT detection from traditional labs to point-of-care settings.

"DVT is a condition where blood clots form in veins, typically in the legs," explained Dr. Satish Muluk, director of vascular surgery at AHN and lead investigator of the trial. "This breakthrough technology has the potential to dramatically improve patient outcomes by accelerating DVT detection and subsequent care."

Traditional DVT detection relies on duplex ultrasounds conducted by trained technicians in dedicated labs. However, ThinkSono's portable technology enables real-time guidance during point-of-care ultrasounds. This innovation allows various healthcare professionals—not just sonogram-trained technicians—to perform imaging procedures.

The clinical trial will compare traditional ultrasounds with those conducted using ThinkSono’s system for accuracy assessment. “Clinicians will capture ultrasound images using handheld devices, and AI will be used to guide them to areas of concern,” said Dr. Muluk.

DVT affects up to 300,000 Americans annually, particularly older or hospitalized individuals due to reduced mobility. Treatment options include anticoagulants or thrombolytics; filters may also be placed for medication-resistant cases.

AGH is one of three institutions involved in this trial, which aims to conclude later this year with results expected for FDA submission.